false
0001022899
0001022899
2026-11-17
2026-11-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
| Date
of Report (Date of Earliest Event Reported): |
|
November
17, 2026 |
Protagenic
Therapeutics, Inc.\new
PROTAGENIC THERAPEUTICS, INC.
(Exact name of Company as specified in its charter)
| Delaware |
|
001-12555 |
|
06-1390025 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
| 149
Fifth Avenue, Suite 500, New York, NY |
|
10010 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
212-994-8200
(Company’s telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any
of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Ticker
symbol(s) |
|
Name
of each exchange on which registered |
| |
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2
of the Securities Exchange Act of 1934.
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry into a Material Definitive Agreement
On
November 10, 2026, Protagenic Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase
Agreement”) with certain accredited investors (the “Purchasers”). Under the Purchase Agreement, the Company agreed
to issue and sell to the Purchasers, in a private placement offering (the “Private Placement”), the following securities
at the Initial Closing (as defined below): (i) 2,459,014 shares of the Company’s common stock, par value $0.0001 per share (the
“Common Stock”); (ii) Series A common stock purchase warrants to purchase up to 2,459,014 shares of Common Stock (the “Series
A Warrants”); and (iii) Series B common stock purchase warrants to purchase up to 2,459,014 shares of Common Stock (the
“Series B Warrants” and, together with the Series A Warrants, the “Common Warrants”).
The
purchase price was $0.61 per share of Common Stock and accompanying Common Warrants. This price equals 90% of the volume weighted average
price of the Common Stock for the 30 consecutive trading days ending on the trading day immediately preceding the date of the Purchase
Agreement. The Purchasers’ subscription amounts were deposited with Odyssey Transfer and Trust Company, as escrow agent, under
an escrow agreement dated as of September 25, 2026. Under the Purchase Agreement, the purchase price per Pre-Funded Warrant and
accompanying Common Warrants is equal to the per-share purchase price minus $0.0001.
The
initial closing of the Private Placement occurred on November 17, 2026 (the “Initial Closing”). At the Initial Closing,
the Company received gross proceeds of approximately $1.5 million, before deducting placement agent fees and other offering expenses.
Under
the Purchase Agreement, the Company may sell additional securities on the same terms at one or more subsequent closings until the earlier
of (i) December 31, 2026 and (ii) the date on which the maximum offering amount has been sold. The maximum offering amount is $3,000,000,
which the Company may increase in its discretion to up to $5,000,000.
Pre-Funded
Warrants. Under the Purchase Agreement, any Purchaser whose purchase of shares of Common Stock in the Private Placement would
otherwise result in that Purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99%
(or, at the Purchaser’s election, 9.99%) of the Company’s outstanding Common Stock immediately following the applicable closing
may elect to purchase pre-funded warrants to purchase shares of Common Stock (the “Pre-Funded Warrants”) in lieu of shares
of Common Stock. The Pre-Funded Warrants, if any, have an exercise price of $0.0001 per share, are immediately exercisable
and remain exercisable until exercised in full. No Pre-Funded Warrants were issued at the Initial Closing.
Common
Warrants. The Common Warrants are exercisable for cash only, beginning immediately upon issuance. The Series A Warrants have
an exercise price of $0.67 per share, equal to 110% of the per-share purchase price. The Series B Warrants have an exercise price of
$0.73 per share, equal to 120% of the per-share purchase price.
Each
Common Warrant expires at 5:00 p.m. (New York City time) on the earliest of:
| |
(i) |
the
fifth anniversary of its issuance date; |
| |
|
|
| |
(ii) |
the
30th day following the last day of any period of 10 consecutive trading days during which the volume weighted average price of the
Common Stock equals or exceeds 200% of the per-share purchase price; and |
| |
|
|
| |
(iii) |
the
30th day following the Company’s public disclosure of the dosing of the tenth patient in its planned Phase 1/2a clinical trial
of PT00114 in Generalized Anxiety Disorder. |
Beneficial
ownership limitation. A holder of a Common Warrant or Pre-Funded Warrant may not exercise any portion of the warrant if the holder,
together with its affiliates, would then beneficially own more than 4.99% (or, at the holder’s election, 9.99%) of the shares of
Common Stock outstanding immediately after giving effect to the exercise.
Covenants.
The Purchase Agreement contains customary representations, warranties and covenants of the Company and the Purchasers, and customary
indemnification obligations. Under the Purchase Agreement, the Company has agreed not to issue or agree to issue shares of Common Stock
or Common Stock equivalents, subject to certain exceptions, from the date of the Purchase Agreement until 45 days after the Effective
Date (as defined in the Purchase Agreement). The Company has also agreed not to enter into any variable rate transaction until the first
anniversary of the Effective Date.
Use
of proceeds. The Company intends to use the net proceeds from the Private Placement for general corporate purposes, including
product development, clinical programs and operating expenses.
Placement
agent. Brookline Capital Markets, a division of Arcadia Securities, LLC (the “Placement Agent”), acted as placement
agent for the Private Placement under a placement agency agreement dated as of June 19, 2026 (the “Placement Agency Agreement”).
Under the Placement Agency Agreement, the Company agreed to pay the Placement Agent a cash fee equal to 7.0% of the aggregate gross proceeds
of the Private Placement, payable at each closing from the escrow account, and a non-accountable expense allowance equal to 1.0% of the
aggregate gross proceeds of the Private Placement, and to reimburse the Placement Agent for certain of its reasonable and documented
out-of-pocket expenses, up to $75,000 without the Company’s prior written approval. The Company also agreed to issue to the Placement
Agent, a number of Placement Agent Warrants equivalent to 7.0% of the total number of Common Warrants issued to investors in the Private
Placement (the “Placement Agent Warrants”). The Company also agreed to indemnify the Placement Agent against certain liabilities.
Pursuant to the Placement Agency Agreement, the Company’s directors, executive officers, employees and certain shareholders entered
into “lock-up” agreements pursuant to which they have agreed, subject to certain exceptions, not to sell or transfer any
securities of the Company that they hold for a period of ninety (90) days from the final closing of the Private Placement.
Registration
rights. In connection with the Private Placement, the Company entered into a Registration Rights Agreement with the Purchasers
(the “Registration Rights Agreement”). Under the Registration Rights Agreement, the Company agreed to file one or more registration
statements with the Securities and Exchange Commission (the “SEC”) to register the resale of the shares of Common Stock sold
in the Private Placement and the shares issuable upon exercise of the Pre-Funded Warrants and Common Warrants. The Company agreed to
file within 45 days and to use commercially reasonable efforts to have the registration statement declared effective within 90 days (or
150 days in the event of a “full review” by the SEC). The Company is subject to liquidated damages if it fails to meet these
deadlines.
Exempt
offering. None of the securities sold in the Private Placement, the Placement Agent Warrants, or the shares of Common Stock issuable
upon exercise of the Pre-Funded Warrants, the Common Warrants and the Placement Agent Warrants, have been registered under the Securities
Act of 1933, as amended (the “Securities Act”). These securities were offered and sold in reliance on the exemption from
registration provided by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
The
Purchase Agreement is filed as an exhibit to this Current Report on Form 8-K to provide investors and stockholders with information regarding
its terms. It is not intended to provide any other factual information about the Company or the Purchasers. The representations, warranties
and covenants in the Purchase Agreement were made solely for the purposes of that agreement and as of specific dates, and solely for
the benefit of the parties to it. They may be subject to limitations agreed upon by the contracting parties, may have been made to allocate
contractual risk among the parties rather than to establish matters as facts, and may be subject to standards of materiality that differ
from those applicable to investors. Investors are not third-party beneficiaries under the Purchase Agreement and should not rely on the
representations, warranties and covenants as characterizations of the actual state of facts or condition of the Company.
The
foregoing descriptions of the Purchase Agreement, the Registration Rights Agreement, the Pre-Funded Warrants,, the Series A Warrants,
the Series B Warrants and the Placement Agent Warrants are not complete. Each is qualified in its entirety by reference to the full text
of the applicable document (or form), filed as Exhibits 10.1, 10.2, 10.3, 10.4, 10.5 and 10.6, respectively, to this Current Report on
Form 8-K and incorporated herein by reference.
Item
3.02 Unregistered Sales of Equity Securities.
The
information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. Based in part
on the representations of the Purchasers in the Purchase Agreement, the offer and sale of the securities in the Private Placement is
exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, and under corresponding provisions
of state securities or “blue sky” laws. Each Purchaser represented that it is an accredited investor and is acquiring the
securities for its own account and not with a view to distribution. The securities were offered without any general solicitation by the
Company or its representatives.
Item
7.01 Regulation FD Disclosure.
On
November 11, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is attached as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated herein by reference into this Item 7.01. The information contained in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, is being furnished
and shall not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated
by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation
language in such filing, except to the extent expressly stated in such filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
The
following exhibits are being filed herewith:
| Exhibit
No. |
|
Description |
| 10.1 |
|
Form of Securities Purchase Agreement |
| 10.2 |
|
Form of Registration Rights Agreement |
| 10.3 |
|
Form of Pre-funded Warrant |
| 10.4 |
|
Form of Series A Warrant |
| 10.5 |
|
Form of Series B Warrant |
| 10.6 |
|
Form of Placement Agent Warrant |
| 99.1 |
|
Press
Release dated November 11, 2026 |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
PROTAGENIC
THERAPEUTICS, INC. |
| |
|
|
| Date:
November 17, 2026 |
By: |
/s/
Bill Nichols |
| |
Name: |
Bill
Nichols |
| |
Title: |
President |
Exhibit
99.1

Protagenic
Therapeutics Announces Private Placement of Up to $5 Million to Advance PT00114 into its First U.S. Clinical Trial in Generalized Anxiety
Disorder
| ● | $1.5
million upfront financing, along with up to $3.5 million upon exercise of milestone-linked
warrants, is expected to fund IND-enabling activities and initiation of the Phase 1/2a trial
of PT00114 |
| ● | Phase
1/2a design is intended to generate both safety data and an early efficacy signal in patients
with GAD within a single study |
| ● | IND
submission targeted for late Q1 2027, incorporating FDA’s pre-IND requests; first patient
dosing targeted for Q2 2027, consistent with the Company’s previously announced first-half
2027 timeline |
| ● | Topline
safety data expected in 2H 2027; exploratory efficacy data expected in 1H 2028 |
NEW
YORK, NY, November 11, 2026 / ACCESS Newswire / — Protagenic Therapeutics, Inc. (OTCQB: PTIX) (“Protagenic”
or the “Company”), a clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for stress-related
neuropsychiatric disorders, today announced a private placement with new and existing investors that provides $1.5 million in upfront
gross proceeds. Up to $3.5 million in additional gross proceeds may be received if two series of milestone-linked warrants are exercised
in full, for total potential gross proceeds of up to $5 million, before deducting placement agent fees and offering expenses.
The
Company intends to use the proceeds to complete IND-enabling activities for PT00114, its lead asset; to initiate its planned Phase 1/2a
clinical trial in Generalized Anxiety Disorder (GAD); and for working capital and general corporate purposes. Brookline Capital Markets,
a division of Arcadia Securities, LLC, is acting as sole placement agent for the financing.
PT00114
Development Update
In
August 2026, Protagenic received written responses from the U.S. Food and Drug Administration (FDA) to its Type B pre-IND meeting request
for PT00114 in GAD. FDA identified no deficiencies that would preclude submission of an IND. Since then, the Company has been incorporating
FDA’s requests into its submission and completing the associated chemistry, manufacturing and controls (CMC) work, including refined
CMC specifications and expanded dose cohorts. The Company has also finalized its Phase 1/2a study design.
The
Phase 1/2a trial will include ascending-dose cohorts that evaluate safety, tolerability and pharmacokinetics, followed by a cohort of
patients with GAD. The patient cohort will further evaluate safety and assess exploratory measures of efficacy, including change from
baseline in Hamilton Anxiety Rating Scale (HAM-A) total score. This design is intended to provide early clinical evidence of PT00114’s
activity in its target population within the Company’s first U.S. study.
First
patient dosing is targeted for the second quarter of 2027, subject to FDA review of the IND, which is consistent with the first-half
2027 timeline the Company previously announced. The Company expects topline safety data in the second half of 2027 and exploratory efficacy
data in the first half of 2028.
The
U.S. program builds on two completed Phase 1 studies of PT00114 conducted outside the United States: a single ascending dose study in
May 2024 and a multiple ascending dose study, for which the Company reported positive topline safety results in December 2025. In the
multiple ascending dose study, PT00114 was well tolerated across all dose levels studied, and no serious adverse events were observed.
“We
are encouraged by FDA’s feedback on our pre-IND package for PT00114 in Generalized Anxiety Disorder, and we are moving quickly
to submit our IND and bring this program into the U.S. clinic,” said Bill Nichols Jr., President of Protagenic. “Our
plan, informed by FDA’s feedback, is designed to establish the safety of our novel neuropeptide along with an early efficacy signal
in patients with Generalized Anxiety Disorder. We expect this financing to take us into the clinic and to the enrollment of our first
patients, which we believe will be a value inflection point for the Company. We continue to pursue strategic options and additional capital
so that our priority R&D work is well resourced.”
About
PT00114
PT00114
is Protagenic’s lead clinical asset. It is a first-in-class investigational neuropeptide and a synthetic analog of teneurin C-terminal
associated peptide (TCAP), a naturally occurring brain peptide thought to help regulate the body’s response to stress. Protagenic
is developing PT00114 for stress-related neuropsychiatric disorders, with an initial focus on Generalized Anxiety Disorder and potential
future applications in PTSD and treatment-resistant depression. PT00114 has completed single ascending dose and multiple ascending dose
Phase 1 studies outside the United States. In the multiple ascending dose study, it was well tolerated with no serious adverse events
observed across dose levels. Protagenic plans to begin its first U.S. clinical trial, a Phase 1/2a study in GAD, in the second quarter
of 2027.
About
Protagenic Therapeutics, Inc.
Protagenic
Therapeutics, Inc. (OTCQB: PTIX) is a clinical-stage biopharmaceutical company dedicated to developing breakthrough peptide-based treatments
for stress-related neuropsychiatric disorders. The Company is headquartered in New York, NY. For more information, visit www.protagenic.com.
The
offer and sale of the foregoing securities is being made in reliance on an exemption from the registration requirement under Section
4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and/or Rule 506(b) of Regulation D promulgated thereunder
and applicable state securities laws, and the securities have not been and will not initially be registered under the Securities Act,
or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an
effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state
securities laws. Pursuant to the terms of the registration rights agreement entered into with the investors, the Company has agreed to
file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) covering the resale of the shares
of common stock and the shares of common stock underlying the pre-funded warrants and common warrants sold in the offering.
This
press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale
of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such state or other jurisdiction.
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include, but
are not limited to, statements regarding: the closing of the financing and the anticipated use of proceeds; the potential exercise of
the milestone-linked warrants and the proceeds from any such exercise; the anticipated timing of the Company’s IND submission,
FDA review, and first patient dosing; the completion of CMC activities; the design, conduct, and timing of data from the planned Phase
1/2a study of PT00114; the Company’s expectations regarding its liquidity, capital resources, and ability to raise additional financing;
and the therapeutic potential of PT00114 in Generalized Anxiety Disorder and other stress-related disorders. These statements are based
on current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance,
or achievements to differ materially from those expressed or implied. These risks include, among others: the Company’s ability
to continue as a going concern; whether milestones are achieved and the warrants are exercised; the availability and terms of additional
financing; the risk of delays in CMC or manufacturing activities; the risk that FDA’s pre-IND advice is non-binding and that FDA
may request additional information, impose a clinical hold, or otherwise delay the program; the inherent uncertainty of clinical development,
including that results from exploratory endpoints or early-stage studies may not be predictive of later results; and other risks described
in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended
March 31, 2026. Because the Company’s common stock may be considered “penny stock,” the statutory safe harbor for forward-looking
statements under the Private Securities Litigation Reform Act of 1995 may not be available to the Company, and the Company therefore
also relies on the protections afforded by the “bespeaks caution” doctrine. Protagenic Therapeutics undertakes no obligation
to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required
by applicable law.
Investor
& Media Contact:
Protagenic
Therapeutics, Inc. | info@protagenic.com | www.protagenic.com